The Challenges of Using Ki67 as a Tool in Breast Cancer

Video

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the difficulties when using Ki67 to measure proliferation in breast cancer.

Clinical Pearls

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the difficulties when using Ki67 to measure proliferation in breast cancer.

  • Ki67 index values are difficult to reproduce between pathologists
Recent Videos
Related Content
A Real-Time Cancer-Detecting System for Breast Cancer Goes Live

A Real-Time Cancer-Detecting System for Breast Cancer Goes Live

Morgan Bayer
January 30th 2025
Article

The LumiSystem detection tool is now commercially available in the US.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer

FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer

Jordyn Sava
January 27th 2025
Article

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results.

Read More

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022
Podcast

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Listen

Elinzanetant Shows VMS Reduction in Women With or at High Risk of HR+ Breast Cancer

Elinzanetant Shows VMS Reduction in Women With or at High Risk of HR+ Breast Cancer

Jordyn Sava
January 22nd 2025
Article

Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in the OASIS 4 trial.

Read More

Long-Term Follow-Up of Ibrutinib/Venetoclax Provides Durable Survival in CLL/SLL

Long-Term Follow-Up of Ibrutinib/Venetoclax Provides Durable Survival in CLL/SLL

Jordyn Sava
January 21st 2025
Article

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Read More